> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# BioMarin's Alesta Purchase Will Cost $320 Million In 2026, Its 8-K Says, And The Forecast Excludes It
- URL: https://www.bullished.co/biomarins-alesta-purchase-will-cost-320-million-in-2026-its-8-k-says-and-the-forecast-ed07e622/
- Published: 2026-10-06T20:36:41.000Z
- Updated: 2026-10-06T20:36:41.000Z
- Description: The company put a $1.55 per-share hit on the full year and said new guidance will come with third-quarter results.
- Author: Matteo Parrino
- Tags: Earnings, BMRN, Industry: Healthcare

BioMarin expects its Alesta Therapeutics purchase to carry [pre-tax charges of about $283 million](https://www.sec.gov/Archives/edgar/data/0001048477/000104847726000019/bmrn-20261006.htm?ref=bullished.co) in the third quarter, according to an 8-K filed Tuesday. Its current full-year forecast does not include the deal.

## What the 8-K says

The [$283 million](https://www.sec.gov/Archives/edgar/data/0001048477/000104847726000019/bmrn-20261006.htm?ref=bullished.co) is acquired in-process research and development expense, the accounting cost of buying drugs still in development. BioMarin bought Alesta, a Dutch private company, and the deal closed on August 31, 2026.

That charge, together with ongoing operating expenses, lowers both standard-accounting (GAAP) and adjusted (non-GAAP) diluted earnings per share by about $1.50 for the third quarter of 2026, the filing says.

For the full year, BioMarin expects total pre-tax charges of about $320 million from the deal. That figure covers the research charge plus ongoing operating expenses, including transaction and transition costs. The company puts the full-year hit at about $1.55 per share on both measures.

## Why the forecast missed it

BioMarin's guidance from August 6, 2026 did not reflect Alesta. The company said it does not forecast acquired research charges, because the occurrence, size and timing of such deals are "inherently uncertain."

The numbers are preliminary and unaudited. The filing says results for the quarter ended September 30, 2026 are not final and remain subject to the company's closing procedures, and actual results could differ from the estimates.

BioMarin shares closed at $56.22 on Tuesday, and the filing was accepted at 4:22 p.m. ET, after the close. The stock was unchanged at $56.22 in Tuesday after-hours trading (market data).

## What to watch

BioMarin said it expects to provide updated full-year 2026 guidance with its third-quarter results. That update is where the Alesta costs will be folded into the company's outlook.

Until the third-quarter report arrives, the $1.55 per share is a preliminary estimate, and the 8-K itself warns it may change.

### Sources

- [8-K Filing — BIOMARIN PHARMACEUTICAL INC (BMRN)](https://www.sec.gov/Archives/edgar/data/0001048477/000104847726000019/bmrn-20261006.htm?ref=bullished.co) — SEC EDGAR